Difference between revisions of "Volunteer Assignments and Opportunities"

[unchecked revision]

Revision as of 17:52, 21 May 2020

Disease	Page Type	Author	Associate Editor	Author Content (Pending or Complete)	Editor Reviewed (Date)
Myeloproliferative Neoplasms (MPN)	Overview		Fabiola Quintero-Rivera (FQR)
Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive	Disease		FQR
Chronic Neutrophilic Leukemia (CNL)	Disease		FQR
Polycythaemia Vera (PV)	Disease		FQR
Primary Myelofibrosis (PMF)	Disease		FQR
Essential Thrombocythaemia (ET)	Disease		FQR
Chronic Eosinophilic Leukemia, Not Otherwise Specified	Disease		FQR
Myeloproliferative Neoplasm (MPN), Unclassifiable	Disease		FQR
Mastocytosis	Overview		FQR
Cutaneous Mastocytosis	Disease		FQR
Systemic Mastocytosis	Disease		FQR
Mast Cell Sarcoma	Disease		FQR
Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2	Overview		FQR
Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement	Disease		FQR
Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement	Disease		FQR
Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement	Disease		FQR
Myeloid/Lymphoid Neoplasms with PCM1-JAK2	Disease		FQR
Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)	Overview		FQR
Chronic Myelomonocytic Leukemia (CMML)	Disease		FQR
Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative	Disease		FQR
Juvenile Myelomonocytic Leukemia (JMML)	Disease		FQR
Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)	Disease		FQR
Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable	Disease		FQR
Myelodysplastic Syndromes (MDS)	Overview		FQR
Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia	Disease		FQR
Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)	Disease		FQR
Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia	Disease		FQR
Myelodysplastic syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with Multilineage Dysplasia	Disease		FQR
Myelodysplastic Syndrome (MDS) with Excess Blasts	Disease		FQR
Myelodysplastic Syndrome (MDS) with Isolated del(5q)	Disease		FQR
Myelodysplastic Syndrome (MDS), Unclassifiable	Disease		FQR
Refractory Cytopenia of Childhood	Disease		FQR

Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms	Overview		Jennelle Hodge (JH)
Myeloid Neoplasms with Germline Predisposition	Overview		JH
Acute Myeloid Leukaemia with Germline CEBPA Mutation	Disease		JH
Myeloid Neoplasms with Germline DDX41 Mutation	Disease		JH
Myeloid Neoplasms with Germline RUNX1 Mutation	Disease		JH
Myeloid Neoplasms with Germline ANKRD26 Mutation	Disease		JH
Myeloid Neoplasms with Germline ETV6 Mutation	Disease		JH
Myeloid Neoplasms with Germline GATA2 Mutation	Disease		JH
Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities	Overview		JH
Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1	Disease		JH
Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Disease		JH
Acute Promyelocytic Leukemia (APL) with PML-RARA	Disease		JH
Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3	Disease		JH
Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214	Disease		JH
Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM	Disease		JH
Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1	Disease		JH
Acute Myeloid Leukemia (AML) with BCR-ABL1	Disease		JH
Acute Myeloid Leukemia (AML) with Mutated NPM1	Disease		JH
Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA	Disease		JH
Acute Myeloid Leukemia (AML) with Mutated RUNX1	Disease		JH
Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes	Disease		JH
Therapy-Related Myeloid Neoplasms	Disease		JH
Acute Myeloid Leukemia (AML), Not Otherwise Specified	Overview		JH
Acute Myeloid Leukemia (AML) with Minimal Differentiation	Disease		JH
Acute Myeloid Leukemia (AML) without Maturation	Disease		JH
Acute Myeloid Leukemia (AML) with Maturation	Disease		JH
Acute Myelomonocytic Leukemia	Disease		JH
Acute Monoblastic and Monocytic Leukemia	Disease		JH
Pure Erythroid Leukemia	Disease		JH
Acute Megakaryoblastic Leukemia (AMKL)	Disease		JH
Acute Basophilic Leukemia	Disease		JH
Acute Panmyelosis with Myelofibrosis	Disease		JH
Myeloid Sarcoma	Disease		JH
Myeloid Proliferations Associated with Down Syndrome	Overview		JH
Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome	Disease		JH
Myeloid Leukemia Associated with Down Syndrome	Disease		JH
Blastic Plasmacytoid Dendritic Cell Neoplasm	Disease		JH
Acute Leukemias of Ambiguous Lineage	Overview		JH
Acute Undifferentiated Leukemia	Disease		JH
Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1	Disease		JH
Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged	Disease		JH
Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified	Disease		JH
Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified	Disease		JH
??Mixed-Phenotype Acute Leukaemia, Not Otherwise Specified (NOS), Rare Types	Disease		JH
??Acute Leukaemias of Ambiguous Lineage, Not Otherwise Specified (NOS)	Disease		JH

Precursor Lymphoid Neoplasms	Overview		Yassmine Akkari (YA)
B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities	Overview		YA
B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1	Disease		YA
B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged	Disease		YA
B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1	Disease		YA
B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy	Disease		YA
B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy	Disease		YA
B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3	Disease		YA
B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1	Disease		YA
B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Disease		YA
B-Lymphoblastic Leukemia/Lymphoma with iAMP21	Disease		YA
B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified	Disease		YA
T-Lymphoblastic Leukemia/Lymphoma	Overview		YA
Early T-Cell Precursor Lymphoblastic Leukemia	Disease		YA
NK-Lymphoblastic Leukemia/Lymphoma	Disease		YA

Mature B-Cell Neoplasms	Overview		Snehal Patel (SP)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Disease		SP
Monoclonal B-cell Lymphocytosis	Disease		SP
B-cell Prolymphocytic Leukemia	Disease		SP
Splenic Marginal Zone Lymphoma	Disease		SP
Hairy Cell Leukemia	Disease		SP
Splenic B-cell Lymphoma/Leukemia, Unclassifiable	Overview		SP
Splenic Diffuse Red Pulp Small B-cell Lymphoma	Disease		SP
Hairy Cell Leukemia Variant	Disease		SP
Lymphoplasmacytic Lymphoma	Disease		SP
Waldenstrom Macroglobulinemia	Disease		SP
IgM Monoclonal Gammopathy of Undetermined Significance	Disease		SP
Heavy Chain Diseases	Overview		SP
Mu Heavy Chain Disease	Disease		SP
Gamma Heavy Chain Disease	Disease		SP
Alpha Heavy Chain Disease	Disease		SP
Plasma Cell Neoplasms	Overview		SP
Non-IgM Monoclonal Gammopathy of Undetermined Signiﬁcance	Disease		SP
Plasma Cell Myeloma	Disease		SP
Plasma Cell Myeloma Variants	Disease		SP
Plasmacytoma	Disease		SP
Monoclonal Immunoglobulin Deposition Diseases	Overview		SP
Primary Amyloidosis	Disease		SP
Light Chain and Heavy Chain Deposition Disease	Disease		SP
Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome	Overview		SP
POEMS Syndrome	Disease		SP
TEMPI Syndrome	Disease		SP
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)	Disease		SP
Nodal Marginal Zone Lymphoma	Disease		SP
Paediatric Nodal Marginal Zone Lymphoma	Disease		SP
Follicular Lymphoma	Disease		SP
Testicular Follicular Lymphoma	Disease		SP
In Situ Follicular Neoplasia	Disease		SP
Duodenal-Type Follicular Lymphoma	Disease		SP
Paediatric-Type Follicular Lymphoma	Disease		SP
Large B-cell Lymphoma with IRF4 Rearrangement	Disease		SP
Primary Cutaneous Follicle Centre Lymphoma	Disease		SP
Mantle Cell Lymphoma	Disease		SP
Leukemic Non-Nodal Mantle Cell Lymphoma	Disease		SP
In Situ Mantle Cell Neoplasia	Disease		SP

Example	Example		Greg Corboy (GC)
Example	Example		GC
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example
Example	Example		Example

Difference between revisions of "Volunteer Assignments and Opportunities"

Revision as of 17:52, 21 May 2020

Navigation menu

Search

@@ Line 6: / Line 6: @@
 !Editor Reviewed (Date)
 |-
-|Myeloproliferative Neoplasms (MPN)||'''''Overview'''''|| ||Fabiola Quintero-Rivera (FQR)
+|'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''|| ||Fabiola Quintero-Rivera (FQR)
 |
 |
 |-
-|Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive||Disease
+|    Chronic Myeloid  Leukemia (CML), BCR-ABL1-Positive||Disease
 | ||FQR
 |
 |
 |-
-|Chronic Neutrophilic Leukemia (CNL)||Disease
+|    Chronic Neutrophilic  Leukemia (CNL)||Disease
 | ||FQR
 |
 |
 |-
-|Polycythaemia Vera (PV)||Disease
+|    Polycythaemia Vera  (PV)||Disease
 | ||FQR
 |
 |
 |-
-|Primary Myelofibrosis (PMF)||Disease
+|    Primary Myelofibrosis  (PMF)||Disease
 | ||FQR
 |
 |
 |-
-|Essential Thrombocythaemia (ET)||Disease
+|    Essential  Thrombocythaemia (ET)||Disease
 | ||FQR
 |
 |
 |-
-|Chronic Eosinophilic Leukemia, Not Otherwise Specified||Disease
+|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
 | ||FQR
 |
 |
 |-
-|Myeloproliferative Neoplasm (MPN), Unclassifiable||Disease
+|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
 | ||FQR
 |
 |
 |-
-|Mastocytosis||'''''Overview'''''|| ||FQR
+|'''''Mastocytosis'''''||'''''Overview'''''|| ||FQR
 |
 |
 |-
-|Cutaneous Mastocytosis||Disease
+|    Cutaneous  Mastocytosis||Disease
 | ||FQR
 |
 |
 |-
-|Systemic Mastocytosis||Disease
+|    Systemic Mastocytosis||Disease
 | ||FQR
 |
 |
 |-
-|Mast Cell Sarcoma||Disease
+|    Mast Cell Sarcoma||Disease
 | ||FQR
 |
 |
 |-
-|Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement  of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2||'''''Overview'''''|| ||FQR
+|'''''Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement  of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2'''''||'''''Overview'''''|| ||FQR
 |
 |
 |-
-|Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement||Disease|| ||FQR
+|    Myeloid/Lymphoid  Neoplasms with PDGFRA Rearrangement||Disease|| ||FQR
 |
 |
 |-
-|Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement||Disease|| ||FQR
+|    Myeloid/Lymphoid  Neoplasms with PDGFRB Rearrangement||Disease|| ||FQR
 |
 |
 |-
-|Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement||Disease|| ||FQR
+|    Myeloid/Lymphoid  Neoplasms with FGFR1 Rearrangement||Disease|| ||FQR
 |
 |
 |-
-|Myeloid/Lymphoid Neoplasms with PCM1-JAK2||Disease|| ||FQR
+|    Myeloid/Lymphoid  Neoplasms with PCM1-JAK2||Disease|| ||FQR
 |
 |
 |-
-|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)||'''''Overview'''''|| ||FQR
+|'''''Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)'''''||'''''Overview'''''|| ||FQR
 |
 |
 |-
-|Chronic Myelomonocytic Leukemia (CMML)||Disease|| ||FQR
+|    Chronic  Myelomonocytic Leukemia (CMML)||Disease|| ||FQR
 |
 |
 |-
-|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative||Disease|| ||FQR
+|    Atypical Chronic  Myeloid Leukemia (aCML), BCR-ABL1 Negative||Disease|| ||FQR
 |
 |
 |-
-|Juvenile Myelomonocytic Leukemia (JMML)||Disease|| ||FQR
+|    Juvenile  Myelomonocytic Leukemia (JMML)||Disease|| ||FQR
 |
 |
 |-
-|Myelodysplastic/Myeloproliferative Neoplasms with Ring  Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)||Disease|| ||FQR
+|     Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts  and Thrombocytosis (MDS/MPN-RS-T)||Disease|| ||FQR
 |
 |
 |-
-|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN),  Unclassifiable||Disease|| ||FQR
+|     Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable||Disease|| ||FQR
 |
 |
 |-
-|Myelodysplastic Syndromes (MDS)||'''''Overview'''''|| ||FQR
+|'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''|| ||FQR
 |
 |
 |-
-|Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia||Disease|| ||FQR
+|    Myelodysplastic  Syndrome (MDS) with Single Lineage Dysplasia||Disease|| ||FQR
 |
 |
 |-
-|Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)||Disease|| ||FQR
+|    Myelodysplastic  Syndrome with Ring Sideroblasts (MDS-RS)||Disease|| ||FQR
 |
 |
 |-
-|Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage  Dysplasia||Disease|| ||FQR
+|    Myelodysplastic  Syndrome with Ring Sideroblasts and Multilineage Dysplasia||Disease|| ||FQR
 |
 |
 |-
-|Myelodysplastic syndrome with multilineage  dysplasiaMyelodysplastic Syndrome (MDS) with Multilineage Dysplasia||Disease|| ||FQR
+|    Myelodysplastic  syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease|| ||FQR
 |
 |
 |-
-|Myelodysplastic Syndrome (MDS) with Excess Blasts||Disease|| ||FQR
+|    Myelodysplastic  Syndrome (MDS) with Excess Blasts||Disease|| ||FQR
 |
 |
 |-
-|Myelodysplastic Syndrome (MDS) with Isolated del(5q)||Disease|| ||FQR
+|    Myelodysplastic  Syndrome (MDS) with Isolated del(5q)||Disease|| ||FQR
 |
 |
 |-
-|Myelodysplastic Syndrome (MDS), Unclassifiable||Disease|| ||FQR
+|    Myelodysplastic  Syndrome (MDS), Unclassifiable||Disease|| ||FQR
 |
 |
 |-
-|Refractory Cytopenia of Childhood||Disease|| ||FQR
+|    Refractory Cytopenia  of Childhood||Disease|| ||FQR
 |
 |
@@ Line 148: / Line 148: @@
 |
 |-
-|Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms||'''''Overview'''''|| ||Jennelle Hodge (JH)
+|'''''Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms'''''||'''''Overview'''''|| ||Jennelle Hodge (JH)
 |
 |
 |-
-|Myeloid Neoplasms with Germline Predisposition||'''''Overview'''''|| ||JH
+|'''''Myeloid Neoplasms with Germline Predisposition'''''||'''''Overview'''''|| ||JH
 |
 |
 |-
-|Acute Myeloid  Leukaemia with Germline CEBPA Mutation||Disease|| ||JH
+|    Acute Myeloid  Leukaemia with Germline CEBPA Mutation||Disease|| ||JH
 |
 |
 |-
-|Myeloid Neoplasms  with Germline DDX41 Mutation||Disease|| ||JH
+|    Myeloid Neoplasms with Germline DDX41  Mutation||Disease|| ||JH
 |
 |
 |-
-|Myeloid Neoplasms  with Germline RUNX1 Mutation||Disease|| ||JH
+|    Myeloid Neoplasms with Germline RUNX1  Mutation||Disease|| ||JH
 |
 |
 |-
-|Myeloid Neoplasms  with Germline ANKRD26 Mutation||Disease|| ||JH
+|    Myeloid Neoplasms with Germline ANKRD26  Mutation||Disease|| ||JH
 |
 |
 |-
-|Myeloid Neoplasms  with Germline ETV6 Mutation||Disease|| ||JH
+|    Myeloid Neoplasms with Germline ETV6  Mutation||Disease|| ||JH
 |
 |
 |-
-|Myeloid Neoplasms  with Germline GATA2 Mutation||Disease|| ||JH
+|    Myeloid Neoplasms with Germline GATA2  Mutation||Disease|| ||JH
 |
 |
 |-
-|Acute Myeloid Leukemia (AML) with Recurrent Genetic  Abnormalities||'''''Overview'''''|| ||JH
+|'''''Acute Myeloid Leukemia (AML) with Recurrent Genetic  Abnormalities'''''||'''''Overview'''''|| ||JH
 |
 |
 |-
-|Acute Myeloid  Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1||Disease|| ||JH
+|    Acute Myeloid  Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1||Disease|| ||JH
 |
 |
 |-
-|Acute Myeloid  Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11||Disease|| ||JH
+|    Acute Myeloid Leukemia with  inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11||Disease|| ||JH
 |
 |
 |-
-|Acute Promyelocytic  Leukemia (APL) with PML-RARA||Disease|| ||JH
+|    Acute Promyelocytic Leukemia (APL) with  PML-RARA||Disease|| ||JH
 |
 |
 |-
-|Acute Myeloid  Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3||Disease|| ||JH
+|    Acute Myeloid Leukemia (AML) with  t(9;11)(p21.3;q23.3); KMT2A-MLLT3||Disease|| ||JH
 |
 |
 |-
-|Acute Myeloid  Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214||Disease|| ||JH
+|    Acute Myeloid Leukemia (AML) with  t(6;9)(p23;q34.1); DEK-NUP214||Disease|| ||JH
 |
 |
 |-
-|Acute Myeloid  Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM||Disease|| ||JH
+|    Acute Myeloid Leukemia (AML) with  inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM||Disease|| ||JH
 |
 |
 |-
-|Acute Myeloid  Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1||Disease|| ||JH
+|    Acute Myeloid Leukemia (AML)  Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1||Disease|| ||JH
 |
 |
 |-
-|Acute Myeloid  Leukemia (AML) with BCR-ABL1||Disease|| ||JH
+|    Acute Myeloid Leukemia (AML) with  BCR-ABL1||Disease|| ||JH
 |
 |
 |-
-|Acute Myeloid  Leukemia (AML) with Mutated NPM1||Disease|| ||JH
+|    Acute Myeloid Leukemia (AML) with  Mutated NPM1||Disease|| ||JH
 |
 |
 |-
-|Acute Myeloid  Leukemia (AML) with Biallelic Mutations of CEBPA||Disease|| ||JH
+|    Acute Myeloid Leukemia (AML) with  Biallelic Mutations of CEBPA||Disease|| ||JH
 |
 |
 |-
-|Acute Myeloid  Leukemia (AML) with Mutated RUNX1||Disease|| ||JH
+|    Acute Myeloid Leukemia (AML) with  Mutated RUNX1||Disease|| ||JH
 |
 |
@@ Line 236: / Line 236: @@
 |
 |-
-|Acute Myeloid Leukemia (AML), Not Otherwise Specified||'''''Overview'''''|| ||JH
+|''Acute Myeloid Leukemia (AML), Not Otherwise Specified''||'''''Overview'''''|| ||JH
 |
 |
 |-
-|Acute Myeloid  Leukemia (AML) with Minimal Differentiation||Disease|| ||JH
+|    Acute Myeloid  Leukemia (AML) with Minimal Differentiation||Disease|| ||JH
 |
 |
 |-
-|Acute Myeloid  Leukemia (AML) without Maturation||Disease|| ||JH
+|   Acute Myeloid Leukemia (AML) without  Maturation||Disease|| ||JH
 |
 |
 |-
-|Acute Myeloid  Leukemia (AML) with Maturation||Disease|| ||JH
+|    Acute Myeloid Leukemia (AML) with  Maturation||Disease|| ||JH
 |
 |
 |-
-|Acute  Myelomonocytic Leukemia||Disease|| ||JH
+|    Acute Myelomonocytic Leukemia||Disease|| ||JH
 |
 |
 |-
-|Acute Monoblastic  and Monocytic Leukemia||Disease|| ||JH
+|    Acute Monoblastic and Monocytic Leukemia||Disease|| ||JH
 |
 |
 |-
-|Pure Erythroid  Leukemia||Disease|| ||JH
+|    Pure Erythroid Leukemia||Disease|| ||JH
 |
 |
 |-
-|Acute  Megakaryoblastic Leukemia (AMKL)||Disease|| ||JH
+|    Acute Megakaryoblastic Leukemia (AMKL)||Disease|| ||JH
 |
 |
 |-
-|Acute Basophilic  Leukemia||Disease|| ||JH
+|    Acute Basophilic Leukemia||Disease|| ||JH
 |
 |
 |-
-|Acute Panmyelosis  with Myelofibrosis||Disease|| ||JH
+|    Acute Panmyelosis with Myelofibrosis||Disease|| ||JH
 |
 |
@@ Line 280: / Line 280: @@
 |
 |-
-|Myeloid Proliferations Associated with Down Syndrome||'''''Overview'''''|| ||JH
+|'''''Myeloid Proliferations Associated with Down Syndrome'''''||'''''Overview'''''|| ||JH
 |
 |
 |-
-|Transient Abnormal  Myelopoiesis (TAM) Associated with Down Syndrome||Disease|| ||JH
+|    Transient Abnormal Myelopoiesis (TAM)  Associated with Down Syndrome||Disease|| ||JH
 |
 |
 |-
-|Myeloid Leukemia  Associated with Down Syndrome||Disease|| ||JH
+|    Myeloid Leukemia Associated with Down  Syndrome||Disease|| ||JH
 |
 |
@@ Line 296: / Line 296: @@
 |
 |-
-|Acute Leukemias of Ambiguous Lineage||'''''Overview'''''|| ||JH
+|'''''Acute Leukemias of Ambiguous Lineage'''''||'''''Overview'''''|| ||JH
 |
 |
@@ Line 304: / Line 304: @@
 |
 |-
-|    Mixed Phenotype Acute Leukemia (MPAL)  with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease|| ||JH
+|    Mixed Phenotype Acute  Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1||Disease|| ||JH
 |
 |
@@ Line 332: / Line 332: @@
 |
 |-
-|Precursor Lymphoid Neoplasms||'''''Overview'''''|| ||Yassmine Akkari (YA)
+|'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''|| ||Yassmine Akkari (YA)
 |
 |
 |-
-|B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic  Abnormalities||'''''Overview'''''|| ||YA
+|'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic  Abnormalities'''''||'''''Overview'''''|| ||YA
 |
 |
 |-
-|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1     ||Disease|| ||YA
+|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease|| ||YA
 |
 |
@@ Line 380: / Line 380: @@
 |
 |-
-|T-Lymphoblastic Leukemia/Lymphoma||'''''Overview'''''|| ||YA
+|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''|| ||YA
 |
 |
@@ Line 396: / Line 396: @@
 |
 |-
-|Mature B-Cell Neoplasms||'''''Overview'''''|| ||Snehal Patel (SP)
+|'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''|| ||Snehal Patel (SP)
 |
 |
@@ Line 420: / Line 420: @@
 |
 |-
-|Splenic B-cell Lymphoma/Leukemia, Unclassifiable||'''''Overview'''''|| ||SP
+|'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''|| ||SP
 |
 |
@@ Line 444: / Line 444: @@
 |
 |-
-|Heavy Chain Diseases||'''''Overview'''''|| ||SP
+|'''''Heavy Chain Diseases'''''||'''''Overview'''''|| ||SP
 |
 |
@@ Line 480: / Line 480: @@
 |
 |-
-|    Monoclonal  Immunoglobulin Deposition Diseases||'''''Overview'''''|| ||SP
+|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''|| ||SP
 |
 |
@@ Line 492: / Line 492: @@
 |
 |-
-|Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome||'''''Overview'''''|| ||SP
+|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''|| ||SP
 |
 |